BioNTech Results Presentation Deck

RiboCytokines: Designed to Overcome Limitations of Recombinant Cytokine Therapy Cytokines encoded by mRNA: A novel therapeutic concept Systemic delivery with minimal immunogenicity Backbone optimized and nucleoside-modified mRNA encoding cytokine fused to human albumin Liver-targeting LNP formulation with intravenous delivery Encoded cytokines translated within cells. ● ● Designed for optimized safety, tolerability and dosing Prolonged serum half-life High bioavailability Lower and less frequent dosing Lower toxicity ● ● ● ● 31 Product Candidate BNT 151 (modified IL-2) BNT152+153 (IL-7 + IL-2) Indication Solid Tumors Solid Tumors Pre-clinical Phase 1 Phase 2 LNP, lipid nanoparticle; PK, pharmacokinetic; IL-2, Interleukin-2; IL7, Interleukin-7; UTR, untranslated region RiboCytokine® is a registered trademark of BioNTech Lipid nanoparticle (LNP) Cap 30 BOB SPO Lipids Serum concentration 5' UTR RiboCytokine RNA Cytokine-Albumin PK profile HM Time Recombinant cytokine RiboCytokine 3' UTR BIONTECH AAA

View entire presentation